These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 26758586)

  • 41. Feasibility re-evaluation of 75 mg/m² docetaxel in Japanese patients with previously treated non-small cell lung cancer.
    Yamada K; Takeoka H; Mizoguchi Y; Yamashita F; Yoshida T; Zaizen Y; Okayama Y; Naito Y; Azuma K; Hoshino T
    Jpn J Clin Oncol; 2014 Apr; 44(4):338-45. PubMed ID: 24482414
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel.
    Di Maio M; Krzakowski M; Fougeray R; Kowalski DM; Gridelli C
    Lung Cancer; 2012 Jul; 77(1):116-20. PubMed ID: 22361218
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer.
    Chung FT; Lee KY; Fang YF; Shieh MH; Lin SM; Yu CT; Lo YL; Lin TY; Kuo CH; Feng PH; Ni YL; Kuo HP
    Chemotherapy; 2011; 57(2):147-55. PubMed ID: 21454972
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
    Schuette W; Nagel S; Blankenburg T; Lautenschlaeger C; Hans K; Schmidt EW; Dittrich I; Schweisfurth H; von Weikersthal LF; Raghavachar A; Reissig A; Serke M
    J Clin Oncol; 2005 Nov; 23(33):8389-95. PubMed ID: 16293869
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy.
    Chen YM; Shih JF; Perng RP; Tsai CM; Whang-Peng J
    Chest; 2006 Apr; 129(4):1031-8. PubMed ID: 16608954
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer.
    Baas P; Szczesna A; Albert I; Milanowski J; Juhász E; Sztancsik Z; von Pawel J; Oyama R; Burgers S
    J Thorac Oncol; 2008 Jul; 3(7):745-50. PubMed ID: 18594320
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.
    Ishimoto O; Sugawara S; Inoue A; Ishida T; Munakata M; Koinumaru S; Hasegawa Y; Suzuki T; Miki H; Saijo Y; Nukiwa T
    J Thorac Oncol; 2006 Nov; 1(9):979-83. PubMed ID: 17409982
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
    Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
    Rodrigues-Pereira J; Kim JH; Magallanes M; Lee DH; Wang J; Ganju V; Martínez-Barrera L; Barraclough H; van Kooten M; Orlando M
    J Thorac Oncol; 2011 Nov; 6(11):1907-14. PubMed ID: 22005471
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
    Lee DH; Park K; Kim JH; Lee JS; Shin SW; Kang JH; Ahn MJ; Ahn JS; Suh C; Kim SW
    Clin Cancer Res; 2010 Feb; 16(4):1307-14. PubMed ID: 20145166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The risk of febrile neutropenia in patients with non-small-cell lung cancer treated with docetaxel: a systematic review and meta-analysis.
    Wailoo A; Sutton A; Morgan A
    Br J Cancer; 2009 Feb; 100(3):436-41. PubMed ID: 19190633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of toxicity of weekly docetaxel in chemotherapy-treated non-small cell lung cancers.
    Chen JP; Lo Y; Yu CJ; Hsu C; Shih JY; Yang CH
    Lung Cancer; 2008 Apr; 60(1):92-97. PubMed ID: 17936403
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
    Miller AA; Wang XF; Gu L; Hoffman P; Khatri J; Dunphy F; Edelman MJ; Bolger M; Vokes EE; Green MR;
    J Thorac Oncol; 2008 Oct; 3(10):1159-65. PubMed ID: 18827613
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
    Hamada H; Irifune K; Ito R; Sakai K; Kadowaki T; Katayama H; Abe M; Shiode M; Nishimura K; Higaki J
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1235-9. PubMed ID: 17687204
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical trial simulations for dosage optimization of docetaxel in patients with liver dysfunction, based on a log-binominal regression for febrile neutropenia.
    Ozawa K; Minami H; Sato H
    Yakugaku Zasshi; 2009 Jun; 129(6):749-57. PubMed ID: 19483418
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study.
    Ulmeanu R; Antohe I; Anisie E; Antoniu S
    Expert Rev Anticancer Ther; 2016; 16(2):165-7. PubMed ID: 26634873
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.
    Fukae M; Shiraishi Y; Hirota T; Sasaki Y; Yamahashi M; Takayama K; Nakanishi Y; Ieiri I
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1013-1023. PubMed ID: 27709284
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dose individualisation in oncology using chemotherapy-induced neutropenia: Example of docetaxel in non-small cell lung cancer patients.
    Lombard A; Mistry H; Aarons L; Ogungbenro K
    Br J Clin Pharmacol; 2021 Apr; 87(4):2053-2063. PubMed ID: 33075149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Desensitisation to circumvent hypersensitivity reactions; treatment with docetaxel still possible].
    Luiting J; de Monchy JG; Hiltermann TJ; Oude Elberink JN
    Ned Tijdschr Geneeskd; 2011; 155():A2980. PubMed ID: 21527052
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.
    Yano R; Konno A; Watanabe K; Tsukamoto H; Kayano Y; Ohnaka H; Goto N; Nakamura T; Masada M
    Int J Clin Oncol; 2013 Feb; 18(1):96-104. PubMed ID: 22095245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.